Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer

View ORCID ProfileHaiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
doi: https://doi.org/10.1101/2021.02.06.21251099
Haiquan Li
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Haiquan Li
  • For correspondence: haiquan@arizona.edu bennettc@cop.sc.edu yves@arizona.edu
Edwin Baldwin
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang Zhang
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen Kenost
4Cancer Center and Department of Medicine, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenting Luo
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Calhoun
2Department of Population Health, University of Kansas Medical Center, Westwood, Kansas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingling An
1Department of Biosystems Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles L. Bennett
3Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, South Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: haiquan@arizona.edu bennettc@cop.sc.edu yves@arizona.edu
Yves A. Lussier
4Cancer Center and Department of Medicine, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: haiquan@arizona.edu bennettc@cop.sc.edu yves@arizona.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Prior research has reported an increased risk of fatality for cancer patients, but most studies investigated the risk by comparing cancer patients to non-cancer patients among COVID-19 infections. Only a few studies have compared the impact of a COVID-19 infection to non-infection with matched cancer patients and types.

Methods & Materials We conducted survival analyses of 4,606 cancer patients with COVID-19 test results from March 16 to October 11, 2020 in UK Biobank and estimated the overall hazard ratio of fatality with and without COVID-19 infection. We also examined the hazard ratios of thirteen specific cancer types with at least 100 patients.

Results COVID-19 resulted in an overall hazard ratio of 7.76 (95% CI: [5.78, 10.40], p<10−10) by studying the survival rate of 4,606 cancer patients for 21-days after the tests. The hazard ratio was shown to vary among cancer type, with over a 10-fold increase in fatality rate (false discovery rate≤0.02) for melanoma, hematologic malignancies, uterine cancer, and kidney cancer using a stratified analysis on each of the cancer types. Although COVID-19 imposed a higher risk for localized cancers compared to distant metastasis ones, those of distant metastasis yielded higher fatality rates due to their multiplicative effects.

Conclusion The results highlight the importance of timely care for localized and hematological cancer patients and the necessity to vaccinate uninfected patients as soon as possible, particularly for the cancer types influenced most by COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study is partially funded by National Cancer Institute (CA023074).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We applied for data access to UK Biobank on December 6, 2017. The University of Arizona signed a Material Transfer Agreement (MTA) for data and/or sample with UK Biobank on February 22, 2018. The application id is 28979, and the PI is Haiquan Li. Per UK Biobank policy, any COVID-19 related research can be done under an existing MTA or an approved project, with no changes or additional fees. On behalf of Application 28979 on April 17, 2020, we registered to access the following data held by UK Biobank: COVID-19 test data, primary care data, hospitalization data, death data, which covers all data used in this study. Ethical approval of the collection of original data of UK Biobank was given by UK National Health Service (NHS) Health Research Authority on May 13, 2016. The research tissue bank title is 'UK Biobank: a large scale prospective epidemiological resource.' The REC reference is 16/NW/0274, and the IRAS project ID is 200778. The IRB covers all projects approved by UK Biobank. University of Arizona Human Subjects Protection Program confirmed that project 28979 did not require a Human Subjects Review on July 5, 2019, due to the usage of de-identified data. The protocol number is 1907756965.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The results will be shared upon request. The original data was from UK Biobank so the access should follow UK Biobank data access application process.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
Haiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
medRxiv 2021.02.06.21251099; doi: https://doi.org/10.1101/2021.02.06.21251099
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
COVID-19 increases age- and sex-controlled 21-day fatality rates for patients with melanoma, hematologic malignancies, uterine cancer, or kidney cancer
Haiquan Li, Edwin Baldwin, Xiang Zhang, Colleen Kenost, Wenting Luo, Elizabeth A. Calhoun, Lingling An, Charles L. Bennett, Yves A. Lussier
medRxiv 2021.02.06.21251099; doi: https://doi.org/10.1101/2021.02.06.21251099

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (194)
  • Anesthesia (54)
  • Cardiovascular Medicine (488)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5664)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (856)
  • Geriatric Medicine (88)
  • Health Economics (229)
  • Health Informatics (759)
  • Health Policy (389)
  • Health Systems and Quality Improvement (250)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6456)
  • Intensive Care and Critical Care Medicine (388)
  • Medical Education (116)
  • Medical Ethics (28)
  • Nephrology (90)
  • Neurology (845)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (161)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (47)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (248)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (113)
  • Psychiatry and Clinical Psychology (961)
  • Public and Global Health (2222)
  • Radiology and Imaging (376)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (311)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)